Immuron Ltd ADR (IMRN)vsInsmed Inc (INSM)
IMRN
Immuron Ltd ADR
$0.81
+3.69%
HEALTHCARE · Cap: $7.18M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 8011% more annual revenue ($606.42M vs $7.48M). INSM leads profitability with a -2.1% profit margin vs -62.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
IMRN
Avoid33
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
4.8% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 27.0x book value
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : IMRN
IMRN has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : IMRN
The primary concerns for IMRN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
IMRN is growing revenue faster at 4.8% — sustainability is the question.
IMRN generates stronger free cash flow (-2M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immuron Ltd ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immunomodulated diseases in Australia, the United States and internationally. The company is headquartered in Carlton, Australia.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?